Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bee venom desensitisation with or without Advax adjuvant
ACTRN12608000379314Phase 2Completed
- Sponsor
- Vaxine
- Start
- May 2008
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bee venom extract and ADVAX in bee venom allergy (2 arms), sponsored by Vaxine. Primary endpoint: Bee venom desensitisation assessed by bee venom skin challenge test. Started May 2008; status: completed.
02
Drugs
bee venom extractADVAX
03
Conditions
bee venom allergy
Beyond the preview
Go deeper on ACTRN12608000379314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000379314.